Share on StockTwits

Equities researchers at Roth Capital increased their target price on shares of EnteroMedics (NASDAQ:ETRM) from $3.00 to $5.00 in a research report issued on Wednesday. The firm currently has a “buy” rating on the stock. Roth Capital’s target price would indicate a potential upside of 228.95% from the company’s current price.

Shares of EnteroMedics (NASDAQ:ETRM) traded up 11.18% during mid-day trading on Wednesday, hitting $1.69. The stock had a trading volume of 12,197,451 shares. EnteroMedics has a one year low of $1.00 and a one year high of $2.66. The stock’s 50-day moving average is $1.82 and its 200-day moving average is $2.02. The company’s market cap is $113.6 million.

EnteroMedics (NASDAQ:ETRM) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). During the same quarter in the previous year, the company posted ($0.14) earnings per share. Analysts expect that EnteroMedics will post $-0.38 EPS for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Canaccord Genuity raised their price target on shares of EnteroMedics to $5.00 in a research note on Monday. They now have a “buy” rating on the stock. Finally, analysts at Northland Securities reiterated a “buy” rating on shares of EnteroMedics in a research note on Monday, April 21st. Five equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $5.20.

EnteroMedics Inc (NASDAQ:ETRM) is a development- stage medical device company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.